HK Stock Market Move | GENFLEET-B(02595) rises over 4% as GFH375/VS-7375 achieves positive progress in multiple domestic and overseas clinical studies

GENFLEET-B(02595) rose over 4%, up 3.8% as of press time, at HK$27.32, with a turnover of HK$41.1573 million. On the news front, on October 15, GENFLEET-B announced that GFH375/VS-7375 (an oral KRAS G12D inhibitor) has achieved positive progress in multiple domestic and overseas clinical studies, and the latest data from the relevant studies have been published. Currently, GFH375 has obtained three Breakthrough Therapy Designations (BTD) in China for the treatment of KRAS G12D-mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), and has entered two registrational Phase III studies for monotherapy in pancreatic cancer and NSCLC. GenFleet's overseas partner Verastem Oncology (Verastem) is expected to launch a registrational Phase III study of VS-7375 in multiple combination regimens (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of PDAC by the end of this year, with progression-free survival (PFS) and objective response rate (ORR) as dual primary endpoints and overall survival (OS) as a secondary endpoint. Consensus on the study protocol has already been reached with the U.S. Food and Drug Administration (FDA).